Qynapse is strongly committed to innovation in the field of neurodegenerative diseases, particularly Alzheimer’s. “By combining the latest advances in neuroimaging and artificial intelligence algorithms, our solutions represent powerful tools for the diagnosis, disease monitoring and patient care for Alzheimer’s disease.”
These results confirmed that the use of a normative database for the interpretation of brain volumetric analysis, such as the QyScore® normative database, can improve the individual assessment of brain neurodegeneration in RRMS patients in the clinical routine setting.
Qynapse is excited to participate in MSVirtual2020 to share and discuss innovative and cutting-edge research in the field of Multiple Sclerosis (MS).
Qynapse is developing collaborations with European and US hospitals to support the diagnosis and monitoring of neurological complications of the virus, by providing QyScore® to automatically quantify brain MRI markers in COVID-19 patients for retrospective or prospective analyses.
QyScore®, the FDA-cleared and CE-marked software commercialized by Qynapse, confirms its value for the rapid measurement of brain atrophy and white matter hyperintensity in a clinical routine setting
Qynapse is thrilled to be part of the Scientific Program of AAIC and the Virtual Exhibition from July 27 to July 31 − to present our latest advances and solutions.
QyScore® allows automated quantification of a broad portfolio of Magnetic Resonance Imaging markers that are key to support early diagnosis and clinical monitoring of neurodegenerative disorders
QyScore®, the software by Qynapse that provides automated volumetric measurements of brain structures, takes a big step forward with the validation of performance for one of its major functionalities
Qynapse is pleased to announce the signing of a partnership agreement with AG Mednet, the leading provider of medical trials data management services, for the use of its Judi imaging adjudication system
On September 20th 2018, Qynapse was featured on the evening news program of the French network France 3 in a report dedicated to Alzheimer’s disease diagnosis
Qynapse is a medical technology company that unlocks the potential of quantitative imaging and AI to optimize diagnosis, prognosis and longitudinal monitoring of patients with neurological diseases.
- Qynapse solutions help experts build understanding, by quantifying precisely and automatically the brain atrophy of… https://t.co/GLKl3JvpH92 days ago
- World Alzheimer’s Day: Read our article and hear expert opinions on how #neuroimaging and #AI offer new opportuniti… https://t.co/xkNuccUaXD9 days ago
- We were pleased to present new data at #MSVirtual2020 demonstrating how our QyScore® software improves the clinical… https://t.co/D0c8y26YLT14 days ago
- Thank you @ACTRIMS @ECTRIMS for this great meeting and virtual experience ! The #MSVirtual2020 platform remains vie… https://t.co/w7y52msOWA16 days ago
130, rue de Lourmel
75015 Paris – France